External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Liver disease

What's new

Sign up or login to unlock the full suite of MEDICALLY features

Nov 4 / Roche and Genentech
High precision analytical performance of a neo-epitope specific novel PRO-C3 immunoassay in human blood-based samples
This single-centre study validated the analytical performance of the novel fully automated Elecsys® PRO-C3 immunoassay (Roche Diagnostics GmbH, Mannheim, Germany) for the quantification of PRO-C3 in human blood samples. Assay limits, linearity, precision, and consistency between reagent lots and cobas e platforms (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) were evaluated. Reference and expected clinically relevant ranges were determined using samples from apparently healthy donors and patients with different chronic liver disease etiologies, respectively.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 4 / Roche and Genentech
High precision analytical performance of a neo-epitope specific novel PRO-C3 immunoassay in human blood-based samples
This single-centre study validated the analytical performance of the novel fully automated Elecsys® PRO-C3 immunoassay (Roche Diagnostics GmbH, Mannheim, Germany) for the quantification of PRO-C3 in human blood samples. Assay limits, linearity, precision, and consistency between reagent lots and cobas e platforms (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) were evaluated. Reference and expected clinically relevant ranges were determined using samples from apparently healthy donors and patients with different chronic liver disease etiologies, respectively.
Upcoming congresses
Access to Roche and Genentech’s latest medical information
View related congresses

Ask a question or share feedback